Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose
BCVA: loss of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Photodynamic therapy with verteporfin leads to lower loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).
1 finding from 1 review
- Photodynamic therapy for neovascular age‐related macular degeneration 2007 · Cochrane Headline outcomes onlyRR 0.8 [0.73, 0.88]4 studies · 1381 participantsHigh